Scientech Research LLC Invests $786,000 in Twist Bioscience Corporation $TWST

Key Points

• Scientech Research LLC acquired a new stake in Twist Bioscience Corporation, purchasing 20,029 shares valued at approximately $786,000 in the first quarter.
• Twist Bioscience reported a loss of $0.47 per share for the last quarter, which was better than the analyst consensus estimate of a loss of $0.54.
• Research analysts have a consensus price target of $49.40 for Twist Bioscience, with nine analysts rating it as a "Buy."

Scientech Research LLC acquired a new stake in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 20,029 shares of the company's stock, valued at approximately $786,000.

A number of other large investors also recently modified their holdings of TWST. Versant Capital Management Inc increased its position in shares of Twist Bioscience by 547.2% in the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after purchasing an additional 580 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after purchasing an additional 303 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Twist Bioscience in the 4th quarter valued at approximately $58,000. Bayforest Capital Ltd grew its position in shares of Twist Bioscience by 49.3% in the 1st quarter. Bayforest Capital Ltd now owns 4,860 shares of the company's stock valued at $191,000 after buying an additional 1,604 shares during the last quarter. Finally, Pallas Capital Advisors LLC purchased a new position in shares of Twist Bioscience in the 1st quarter valued at $201,000.

Twist Bioscience Stock Performance

NASDAQ:TWST traded down $0.30 during trading hours on Friday, reaching $25.31. 1,502,508 shares of the company's stock were exchanged, compared to its average volume of 1,300,645. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of -17.46 and a beta of 2.31. The company has a 50-day moving average of $30.52 and a 200 day moving average of $34.18. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 1-year low of $24.07 and a 1-year high of $55.33.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. The firm had revenue of $96.06 million during the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Adam Laponis sold 2,449 shares of the firm's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total value of $93,429.35. Following the completion of the sale, the chief financial officer owned 103,569 shares in the company, valued at approximately $3,951,157.35. This trade represents a 2.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 2,265 shares of the firm's stock in a transaction on Monday, September 8th. The stock was sold at an average price of $25.76, for a total transaction of $58,346.40. Following the completion of the sale, the chief executive officer owned 634,740 shares of the company's stock, valued at $16,350,902.40. This trade represents a 0.36% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,911 shares of company stock valued at $288,159. 3.01% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

TWST has been the topic of a number of recent analyst reports. Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Evercore ISI set a $46.00 target price on shares of Twist Bioscience in a research report on Monday, August 4th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $49.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.